Emergent BioSolutions (EBS)
Healthcare · Drug Manufacturers - Specialty & Generic
1 member of Congress has disclosed 1 trade in Emergent BioSolutions (EBS) since 2024: 0 buys and 1 sale. The most recent was disclosed on Jan 10, 2025.
- Trades disclosed
- 1
- Members trading
- 1
- Buys / sells
- 0 / 1
- Reported value
- $1K–$15K
Keep following the company.
Subscribers get new congressional filings and notable insider purchases for companies they follow. Coverage varies by company.
What else is happening at EBS
All research →Company filings and public records connected to this stock, ordered by when they became public or were first observed.
EBS: third_quarter 2026 lobbying report
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical de
Public: Oct 19, 2026, 4:27 PM EDTOriginal source ↗EBS: third_quarter 2026 lobbying report
- Reauthorization of Protecting Americans from All-Hazards Preparedness Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY27 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27 - Tribal Opioid Response Grant funding for FY27 - H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and che
Public: Oct 13, 2026, 3:57 PM EDTOriginal source ↗EBS: second_quarter 2026 lobbying report
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical de
Public: Jul 19, 2026, 11:16 AM EDTOriginal source ↗EBS: second_quarter 2026 lobbying report
- Reauthorization of Protecting Americans from All-Hazards Preparedness Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY27 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27 Tribal Opioid Response Grant funding for FY27 H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical
Public: Jul 14, 2026, 12:00 PM EDTOriginal source ↗
Who traded EBS
- Rep. Steve Cohen (D-TN-9)0 buys · 1 sale01Jan 10, 2025
All trades
- Jan 10, 2025$1K–$15K
Rep. Steve Cohen (D-TN-9)
Sold Emergent BioSolutions EBS
$1K–$15K · Traded Dec 11, 2024 · disclosed Jan 10, 2025
From periodic transaction reports filed under the STOCK Act. Amounts are the ranges members report, and trades can be disclosed up to 45 days after they happen. Nothing here is investment advice.